SUPPLEMENTARY DATA

Supplementary Table1. Number (%) of ACCORD Lipid Trial participants who had a 30% Reduction in HDL-C from baseline to either the 24 and 48 month post-randomization visits, by treatment group and TZD use at visit-specific blood draws*

A) Outcome: Having a 30% Drop in HDL-C from Baseline Visit to Specified Post-Randomization Visit.

On TZD at Visit-specific Blood Draw?	At 24 Month Post-RZ Visit (N=4852 with HDL-C Value and TZD use data)			At 48 Month Post-RZ Visit (N=3531 with HDL-C value and TZD use data)		
	Fenofibrate	Placebo	Total	Fenofibrate	Placebo	Total
Yes	89/1412 (6.3%)	13/1375 (0.9%)	102/2787 (3.7%)	51/801 (6.4%)	7/767 (0.9%)	58/1568 (3.7%)
No	16/1033 (1.5%)	15/1032 (1.5%)	31/2065 (1.5%)	30/968 (3.1%)	10/995 (1.0%)	40/1963 (2.0%)
Total	105/2445 (4.3%)	28/2407 (1.2%)	133/4852 (2.7%)	81/1769 (4.6%)	17/1762 (1.0%)	98/3531 (2.8%)

B) Outcome: Having a 30% Drop in HDL-C from Baseline Visit to Specified Post-Randomization Visit AND an HDL-C < 25 mg/dl (<0.647 mmol/L) at the Post-Randomization Visit.

On TZD at Visit-specific Blood Draw?	At 24 Month Post-RZ Visit (N=4852 with HDL-C Value and TZD use data)			At 48 Month Post-RZ Visit (N=3531 with HDL-C value and TZD use data)		
	Fenofibrate	Placebo	Total	Fenofibrate	Placebo	Total
Yes	71/1412 (5.0%)	4/1375 (0.3%)	75/2787 (2.7%)	41/801 (5.1%)	4/767 (0.5%)	45/1568 (2.9%)
No	6/1033 (0.6%)	6/1032 (0.6%)	12/2065 (0.6%)	13/968 (1.3%)	3/995 (0.3%)	16/1963 (0.8%)
Total	77/2445 (3.1%)	10/2407 (0.4%)	87/4852 (1.8%)	54/1769 (3.1%)	7/1762 (0.4%)	61/3531 (1.7%)

*Data are presented as number (%). Denominators for percents are the cell-specific numbers of lipid trial participants who had an HDL-C measurement at the specified visit and for whom the concomitant use or nonuse of a TZD was recorded on study forms. Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes; TZD, thiazolidinedione; RZ, randomization.

SUPPLEMENTARY DATA

Supplementary Figure 1. Cumulative percent of participants with an absolute change in HDL-C from baseline to month 24 (A) or month 48 (B) that is equal to or less than the value specified on the X-axis, by lipid treatment group assignment and use of a TZD at time of visit-specific blood draw. Abbreviations: TZD, thiazolidinedione; Mn, Mean HDL-C value in group at visit in mg/dl; N, number of participants in group. To convert HDL-C to millimoles per liter, multiply by 0.02586.

A) From Baseline to the 24 Month Post-Randomization Visit



B) From Baseline to the 48 Month Post-Randomization Visit